Margin Halved, Profit Crashed; Price Hikes Miss All Guidance
Radiant Cash delivered ₹109.5 Cr revenue and ₹2.1 Cr profit—a 73% collapse that smashes guidance targets. Management credits manpower cost spikes and delays the benefit of secured 12-15% price increases to Q4. The credibility gap is widening.
₹109.5 Cr
+4.6% YoY, +3.6% QoQ
₹2.1 Cr
-73.2% YoY, -60.7% QoQ
7.62%
Down from 15.2% YoY
1.8%
Down from 6.2% YoY
Radiant Cash delivered a quarter that squarely missed the bar set by its own guidance. Revenue growth of 4.6% year-over-year—and cash handled flat at ₹0.41 trillion—fell well short of the double-digit growth promised for FY27. More damaging, net profit crashed 73% while net margins compressed from 6.2% to 1.8%. EBITDA margin, the operational health metric that matters most for a cash-handling business, was halved from 15.2% to 7.62%. The culprit is unambiguous: manpower costs spiked on minimum wage hikes and armed guard shortages, consuming 70% of the total cost base. Management's answer is a price-hike strategy (12-15% increases secured industry-wide), but most of that benefit won't land until Q4.
Claims vs. Reality: Management's Guidance Scorecard
Double-digit revenue growth
+4.6% YoY; +3.6% QoQ
Missed—off pace by half
FY27 EBITDA margin 17-18% (contingent on price revision)
7.62% (Standalone); 6.8% (Consolidated)
Contradicted—margin halved, not supported
Acemoney to reach EBITDA breakeven in Q3
Still 'near breakeven' in Q2; turnaround lagging
Overstated—timeline slipping
Subsidiaries to turn profitable in H2 FY27
RVL growing 35% Q1-Q2 but not yet profitable; Acemoney not yet breakeven
Overstated—profitability push delayed
Direct client revenue targeting ~33% of revenue within 1-2 years
19.2% in Q2 (up from 15.7% YoY); slow progression
Supported but execution unproven at scale
What Changed on This Call
Three material shifts in the narrative:
Price hike strategy deployed: 12-15% increases secured from majority of clients (banks, retail). Banks from 1 Nov; retail from 1 Dec. Benefit accrual concentrated in Q4 FY27 and FY28.
Subsidiary profitability pushed back: Acemoney 'near breakeven,' not yet profitable. RVL ₹29.9 Cr revenue with 35% sequential growth but still in ramp phase. H2 FY27 target now uncertain.
Direct client base becoming core strategy: Shifting away from bank-dependent growth (80% of revenue, decelerating) to direct corporate clients (20% now, targeting 33%). Hiring sector specialists for retail, NBFCs, hospitals.
The Profitability Math: Price Hikes vs. Structural Costs
The debate on this call crystallized around one uncomfortable question: how does a company recovering from a 50% margin collapse get back to 20% profitability (IPO-level) with just a 12-15% price hike and unquantified tech cost cuts? Analyst Dilip pressed hard. Management's answer rested on three pillars: (1) price hikes of 12-15% now embedded in majority client contracts; (2) technology-driven cost optimization (unspecified); (3) subsidiary profitability contribution by H2 FY27 (timing uncertain). None of these levers was sized quantitatively. Col David Devasahayam defended the confidence: 'The worst is behind us.' Analysts Keshav Garg and Dilip remained unconvinced.
Significant increase in manpower costs triggered by revision in minimum wages and shortage of armed gunner and higher van costs resulted in lower profitability for this quarter.
This framing is honest but incomplete. Manpower costs are 70% of the cost base, and they're structural in India's cash management business—minimum wage hikes are state-mandated, guard shortages are acute in southern states, and competitors are facing the same wage inflation. The real question isn't whether price hikes are justified (they are—industry-wide) but whether the Q4 impact will be as 'steady and good' as management claimed. Most bank hikes came through on 1 Nov; retail slower. Gunman shortage remains acute.
Street Positioning: How the Market is Reading This
The stock has taken a beating. At ₹33.12, it sits 70.4% below its all-time high of ₹112.05, though it's recovered 7.85% from its 52-week low of ₹30.71. It trades above its 20-day moving average but well below both the 50-day (₹34.87) and 200-day (₹38.29) averages. RSI at 46.2 is neutral—no signs of capitulation, but no momentum either. Volume is normal.
The ownership picture is striking. FII ownership has collapsed to 0.17% (from 0.45% a year ago). DII is minimal at 0.66%. Promoters hold steady at 56.95%, unchanged quarter-over-quarter. This is a classic pattern of institutional retreat after an IPO disappointment. When the IPO promised ₹112 and the company misses guidance at ₹33, foreign and domestic institutions exit. The stock is left to retail, insiders, and those too illiquid to sell.
The market's own verdict, then, is clear: miss guidance hard enough, and no amount of 'confident' forward messaging holds the tape. The price action confirms the fundamental read—this quarter was a step backward, not a step toward IPO-level profitability.
Ranked Risks: What Should Concern a Holder Most
The Bull-Bear Ledger
12-15% price hikes are secured and embedded in majority of client contracts (banks from 1 Nov, retail from 1 Dec)
Direct client base strategy is sound: 19.2% revenue now, targeting 33% within 1-2 years, higher-margin recurring model
Subsidiary growth is real: RVL ₹29.9 Cr revenue, +35% Q1-Q2; Acemoney near breakeven with sound box and QR deployment scaling
Risk management culture is best-in-class: gross cash losses ₹1 million (0.0002% of ₹0.41 trillion handled)
Market penetration is low (~1.5%); long-term cash management growth structural in India
Guidance miss is severe and unexplained: Double-digit growth (delivered 4.6%), EBITDA 17-18% (delivered 7.62%), H2 subsidiary profitability (pushed back). No formal withdrawal, just reaffirmation.
Profit recovery path is unquantified: Tech cost cuts cited but not sized; unspecified as percentage of cost base or timeline
Manpower cost inflation is structural and ongoing: 70% of cost base affected; no visibility on wage easing
FII/DII ownership has collapsed: FII 0.17%, DII 0.66%. Institutions are exiting, leaving retail and illiquid holders
Price hike benefit is backloaded to Q4 and uncertain: Bank hikes from 1 Nov, retail from 1 Dec. No pre-announcement on realization % or competitive pressure
Stock is 70.4% below ATH and trading below 50-day and 200-day moving averages
The Debate
What to Watch Next
1 · Q4 FY27 price hike impact (early FY28 guidance)
The majority of 12-15% hikes take effect from 1 Nov (banks) and 1 Dec (retail). Q4 results (expected Feb/Mar 2027) or early FY28 guidance will show whether the benefit is as 'steady and good' as management claimed. Watch EBITDA margin recovery and NPM expansion. If they miss again, the credibility gap becomes a chasm.
2 · Acemoney and RVL profitability contribution
Management promised both to turn profitable in H2 FY27 (Q3 and Q4). Watch whether Acemoney reaches breakeven in Q3 (they said 'near' in Q2) and whether RVL crosses into positive PAT. If both slip into FY28, consolidated profit recovery is delayed again.
3 · Direct client base traction (% of revenue and growth rate)
The pivot away from bank-dependent growth (80%, decelerating) to direct clients (19.2% now, targeting 33%) is the medium-term story. Watch Q3-Q4 mix, whether direct client growth accelerates to 25%+ of revenue, and whether the margin uplift materializes. This is the 'prove-it' moment for management's strategic pivot.
The Honest Read
Radiant Cash is not in collapse—its business is sound, its risk management best-in-class, its market penetration low with structural tailwinds. But this quarter is a step backward, and management's reaffirmation of confidence without new numbers is not credible. They missed double-digit growth (delivered 4.6%), halved EBITDA margin (17-18% → 7.62%), and pushed back subsidiary profitability. The price hike strategy is real and will help, but it's backloaded to Q4 and not sufficient on its own to restore 20% profitability.
Recovery is possible—and priced into the stock (70% discount to ATH, well below 50-day/200-day averages). But it's not assured, and it's highly execution-dependent. The company needs: (1) price hikes to hold through Q4 without competitive response; (2) subsidiaries to actually turn profitable (not just 'near breakeven'); (3) direct client base to scale to 25%+ of revenue. Any slip on any of these axes extends the turnaround.
Verdict: Hold. Not a buy until management quantifies the path to 15%+ EBITDA margin and proves subsidiary profitability in Q3. Not a sell unless competitive undercutting emerges or wage inflation accelerates further. The stock reflects a deep turnaround. Watch Q4 results (early 2027) and FY28 guidance closely—that's when the story either resets or continues.
Informational and educational content only. Not investment advice.